Semax

Overview

Semax is a synthetic heptapeptide built from a fragment of adrenocorticotropic hormone, ACTH(4-7), with an added Pro-Gly-Pro sequence intended to slow its breakdown by peptidases. It has been studied in Russia for decades, primarily as an intranasal nootropic and neuroprotective agent, with most of the rigorous published evidence coming from animal models of stroke (ischemia) and, more recently, Alzheimer's disease.

Proposed Mechanism of Action

The research cited here points to two overlapping mechanisms: upregulation of brain-derived neurotrophic factor (BDNF) expression via melanocortin receptor 4 (MC4R) agonism, and broader transcriptional effects on immune- and vascular-system genes in brain tissue following ischemic injury (Medvedeva et al., 2014).

Research Context

The 2014 BMC Genomics study used genome-wide transcriptional analysis in a rat focal-ischemia (stroke) model to characterize how Semax shifts gene expression, with the largest effects seen around 24 hours post-injury. The 2025 Acta Naturae study tested Semax and a derivative peptide in a transgenic mouse model of Alzheimer's disease, reporting improved performance on cognitive tests (open field, novel object recognition, Barnes maze) and reduced amyloid plaque burden in treated animals.

Limitations of the Current Evidence

• Both cited studies are animal models; robust, large-scale human clinical trial data in the peer-reviewed international literature is limited, despite Semax's long history of use in Russian clinical practice under separate regulatory pathways.
• Much of the historical Semax literature is published in Russian-language journals and is harder to independently verify than the English-language studies cited here.